

DAFTAR PUSTAKA

1. Bartolf A, Cosgrove C. Pneumonia. *Medicine*. 2016;44(6):373–377.
2. Balitbang Kemenkes RI. Riset Kesehatan Dasar 2013. Jakarta: Balitbang Kemenkes RI; 2013.
3. Banaszak I, Breborowicz A. Pneumonia in Children. Poland: Intech; 2013.
4. Kemenkes RI. Profil Kesehatan Indonesia 2018. Jakarta: Kemenkes RI; 2019.
5. Dinas Kesehatan Kota Padang. Profil Kesehatan Kota Padang Tahun 2017. Padang: Dinas Kesehatan Kota Padang; 2018.
6. Almasdy D, Deswinar, Helen. Evaluasi Penggunaan Antibiotika pada suatu Rumah Sakit Pemerintah di Kota Padang. Prosiding Seminar Nasional Perkembangan Terkini Sains Farmasi dan Klinik III; 2013.
7. WHO-UNICEF. Pneumonia the Forgotten Killer of Children. Geneva: United Nations Children’s Fund/World Health Organization; 2006.
8. Brunton L, Chabner B, Knollman B. Goodman & Gilman’s the Pharmacological Basic of Therapeutics 12th Edition. New York: Mc Graw Hill; 2011.
9. Nga Tong, BA M. Priority Medicines for Europe and the World “A Public Health Approach to Innovation”: Pneumonia. 2013.
10. RSUP Dr. M. Djamil. Panduan Penggunaan Antibiotik RSUP Dr. M. Djamil Padang. Padang: RSUP Dr. M. Djamil; 2018.
11. Kemenkes RI. Pedoman Pelayanan Kefarmasian untuk Terapi Antibiotika. Jakarta: Kemenkes RI; 2011.
12. Lubis VA, Katar Y, Bahar E. Identifikasi bakteri infeksi saluran pernapasan bawah non tuberkulosis (Non TB) dan pola resistensinya pada penderita diabetes melitus di RSUP M. Djamil. *Jurnal Kesehatan Andalas*. 2016;5:3.
13. Siregar CJ. Farmasi Klinik: Teori dan Penerapan. Jakarta: Penerbit Buku Kedokteran EGC; 2006.

14. Menteri Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 58 Tahun 2014 Tentang Standar Pelayanan Kefarmasian di Rumah Sakit. Jakarta: Menteri Kesehatan Republik Indonesia; 2014.
15. Shivhare S, Kunjwani H, Manikrao A, Bondre A. Drugs hazards and rational use of drugs: A review. *Journal of Chemical and Pharmaceutical Research*. 2010;2(1):106–112.
16. Kemenkes RI. Modul Penggunaan Obat Rasional. Jakarta: Kemenkes RI; 2011.
17. Juwita DA, Arifin H, Yulianti N. Kajian deskriptif retrospektif regimen dosis antibiotik pasien pneumonia anak di RSUP Dr. M. Djamil Padang. *Jurnal Sains Farmasi & Klinis*. 2017;3(2):128-133.
18. Tambun SH, Puspitasari I, Safitri I. Evaluasi luaran klinis terapi antibiotik pada pasien Community Acquired Pneumonia anak rawat inap. *Jurnal Manajemen dan Pelayanan Farmasi*. 2019;9(3):213–224.
19. Walker R, Whittlesea C. *Clinical Pharmacy and Therapeutics*. 5th ed. London: Churchill Livingstone Elsevier; 2012.
20. Mackenzie G. The definition and classification of pneumonia. *Pneumonia*. 2016;8(14):1–5.
21. Nguyen TK, Tran TH, Roberts CL, Fox GJ, Graham SM, Marais BJ. Risk factors for child pneumonia- focus on the Western Pacific Region. *Pediatric Respiratory Review*. 2016.
22. Balitbang Kementrian Kesehatan RI. Laporan Nasional Riset Kesehatan Dasar 2018. Jakarta: Balitbang Kementrian Kesehatan RI; 2018.
23. World Health Organization. Pneumonia [Internet]. Diakses tanggal 14 Oktober 2019. Available from: <https://www.who.int/news-room/fact-sheets/detail/pneumonia>
24. Misnadiarly. Penyakit Infeksi Saluran Napas Pneumonia Pada Anak, Orang Dewasa, Usia Lanjut. Jakarta: Pustaka Obor Popular; 2008.

25. Kemenkes RI. Pedoman Tatalaksana Pneumonia Balita. Jakarta: Kemenkes RI; 2015.
26. Perhimpunan Dokter Paru Indonesia. Pneumonia Komunitas Pedoman Diagnosis & Penatalaksanaan di Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia; 2014.
27. Cilloniz C, Cardozo C, Vidal CG. Epidemiology, pathophysiology, and microbiology of communityacquired pneumonia. *Annals of Research Hospitals*. 2018;2(1):1–11.
28. American Thoracic Society. What is pneumonia?. *American Journal of Respiratory Critical Care Medicine*. 2016;193:1–2.
29. NICE. Pneumonia in Adults: Diagnosis and Management. National Institute for Health and Care Excellence; 2014.
30. Brar N, Nielderman M. Management of Community-Acquired Pneumonia: A review and update. *Therapeutic Advance Respiratory Disease*. 2011;5(1):61–78.
31. Watskin RR, Lemonovich TL. Diagnosis and management of Community-Acquired Pneumonia in adults. *American Family Physician*. 2011;83(11):1299–1306.
32. Tjay TK, Rahardja K. Obat-obat Penting: Khasiat, Penggunaan, dan Efek-Efek Sampingnya. Jakarta: PT Elex Media Komputindo; 2015.
33. Katzung BG, Masters SB, Trevor AJ. *Basic & Clinical Pharmacology*. 12th ed. New York: Mc Graw-Hill; 2012.
34. Geografi L, Wahyono D, Yasin NM. Evaluasi penguunaan antibiotik untuk terapi infeksi saluran kemih pada pasien sindrom nefrotik pediatri. *Jurnal Manajemen dan Pelayanan Farmasi*. 2014;4(1):1–6.
35. Etebu E, Ariekpar I. Antibiotics: Classification and mechanisms of action with emphasis on molecular perspectives. *International Journal of Applied Microbiology and Biotechnology Research*. 2016;4(6):90–101.
36. Brunton LL, Lazo JS, Parker KL. *Goodman & Gillman's the Pharmacological Basis of Theurapeutics*. 11th ed. New york: Mc Graw-Hill; 2006.

37. Ullah H, Ali S. Classification of Anti-Bacterial Agents and Their Functions. Pakistan: Intech; 2017.
38. Radji M. Mekanisme Aksi Molekuler Antibiotik dan Kemoterapi. Jakarta: Penerbit Buku Kedokteran EGC; 2015.
39. Wenczewicz TA. Crossroads of antibiotic resistance and biosynthesis. *Journal of Molecular Biology*. 2019;431(18):3370–3399.
40. Bisth R, Katiyar A, Singh R, Mittal P. Antibiotic resistance- a global issue of concern. *Asian Journal of Pharmaceutical and Clinical Research*. 2009;2(2):34–39.
41. British Thoracic Society. Guidelines for the management of community acquired pneumonia in children: update 2011. *Thorax an International Journal of Respiratory Medicine*. 2011;66.
42. Kementrian Kesehatan Republik Indonesia. Farmakope Indonesia Edisi V. Jakarta: Direktorat Jendral Bina Kefarmasian dan Alat Kesehatan; 2014.
43. Kaushik D, Mohan M, Borade D, Swami O. Ampicillin: Rise fall and resurgence. *Journal of Clinical and Diagnostic Research*. 2014;8(5):1–3.
44. Clark MA, Finkel R, Rey JA, Whalen K. *Lippincott's Illustrated Reviews: Pharmacology*. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2012.
45. Subrahmanyam N, Lakshmi T V, Raju N, Kumar P. Cefotaxime induced macular rash. *Saudi Journal of Medical and Pharmaceutical Science*. 2018;4(9):1032–1034.
46. Rochon ME, Moussa A, Autmizguine J. *Infectious Disease and Pharmacology: Antibiotic Considerations for Necrotizing Enterocolitis*. California: Elsevier; 2019. 155-166.
47. Sweetman SC. *Martindale: The Complete Drug Reference*. 36th Edition. Chicago: Pharmaceutical Press; 2009.
48. Menteri Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Indonesia Nomor 72 Tahun 2016. Jakarta: Menteri Kesehatan Republik Indonesia; 2016.

49. American Society of Health-System Pharmacists. ASHP Guidelines on Medication-Use Evaluation. American Journal of Health System Pharmacy. 1986;53:220–222.
50. Mariam AH, Raghavendra Y, Bobasa EM. Evaluating rational drug use with the help of World Health Organization's core indicators in Bule Hora Hospital, Southern Ethiopia. Gaziantep Medical Journal. 2015;21(2):108–113.
51. World Health Organization. Promoting Safety of Medicines for Children. Switzerland: World Health Organization Press; 2007.
52. Falagas ME, Mourtzoukou EG, Vardakas KZ. Sex differences in the incidence and severity of respiratory tract infection. Respiratory Medicine. 2007;101: 1845-1863.
53. Sunyataningkamto , Iskandar Z, Alan RT. The role of indoor air pollution and other factors in the incidence of pneumonia in under five children. Paediatrica Indonesiana. 2004; 44(1-2):25-29.
54. Farida Y, Trisna A, Nur D. Study of antibiotic use on pneumonia patient in Surakarta Referral Hospital. Journal of Pharmaceutical Science and Clinical Research. 2017;02: 44-52.
55. Hartati S, Nurhaeni N, Gayatri D. Faktor risiko terjadinya pneumonia pada anak balita. Jurnal Keperawatan Indonesia. 2012; 15(1): 13-20.
56. Ikatan Dokter Anak Indonesia. Pedoman Pelayanan Medis Ikatan Dokter Anak Indonesia. Jakarta: Ikatan Dokter Anak Indonesia; 2009.
57. Monita O, Yani FF, Lestari Y. Profil pneumonia komunitas di Bagian Anak RSUP Dr. M.Djamil Padang Sumatera Barat. Jurnal Kesehatan Andalas. 2015; 4(1):218-226.
58. Marcus L, Paul M, Elphick H, Leibovici L. Clinical implications of beta-laktam-aminoglycoside synergism systematic review of randomised trials. International Journal of Antimicrobial Agents. 2011;37:491-503.
59. Anwar Y, Horang ME. Evaluasi penggunaan antibiotika pada pengobatan penderita pneumonia anak di Instalasi rawat inap RSUD Prof. Dr.W. Z.

- Johannes Kupang periode Januari- Juni 2015. *Pharmacy*; 2016;13(02):252-260.
60. Eliopoulos GM, Eliopoulos CT. Antibiotic combination: should be tested?. *Clinical Microbiology Reviews*. 1988;1(2):139-156.
 61. Almasdy D, Harisman, Kurniasih N, Febriandi H. Analisa biaya terapi penyakit bronkopneumonia pada suatu Rumah Sakit Pemerintah di Kota Padang Sumatera Barat. *Prosiding Seminar Nasional dan Workshop "Perkembangan Terkini Sains Farmasi dan Klinik IV"*. 2014: 181-186.
 62. Aryani DE, Hasmono D, Zairina N, Setiawan L. Analysis of antibiotics use in pediatric pneumonia patients aged 3 months- 5 years. *Folia Medica Indonesiana*: 2016;52 (2): 108-115.
 63. Wells BG, Schwinghammer TL, Dipro JT. *Pharmacotherapy Handbook Tenth Edition*. New York: McGraw Hill; 2017.
 64. American Society of Health-Systems Pharmacists. *AHFS Drug Information Essentials*. Bethesda: American Society of Health-Systems Pharmacists Customer Service Departement; 2011.
 65. Nuryati. *Farmakologi*. Jakarta: Kementerian Kesehatan RI; 2017.
 66. Dahlan S. *Statistik untuk Kedokteran dan Kesehatan . Seri Evidence Based Medicine 2 Edisi 3*. Jakarta: Salemba Medika; 2008.
 67. Setiadi F, Kumala S, Utami H, Subhan A. Analisis faktor-faktor yang mempengaruhi outcome terapi pasien pneumonia di Rumah Sakit Umum Pusat Fatmawati Jakarta. *Jurnal Kesehatan Tadulako*; 2019;5(3):1-80.
 68. Rumende CM, Chen LK, Karuniawati A, Bratanata J. Evaluasi antara ketepatan pemberian antibiotik berdasarkan alur gysSENS dengan perbaikan klinis pasien pada pneumonia komunitas. *Jurnal penyakit Dalam Indonesia*; 2019;6(2): 71-77.